Cargando…

Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature

Tumor necrosis factor inhibitors (anti-TNFs) are widely used therapies for the treatment of inflammatory bowel diseases (IBD); however, their administration is not risk-free. Heart failure (HF), although rare, is a potential adverse event related to administration of these medications. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Grillo, Thais Gagno, Silveira, Caroline Ferreira da Silva Mazeto Pupo, Quaglio, Ana Elisa Valencise, Dutra, Renata de Medeiros, Baima, Julio Pinheiro, Bazan, Silmeia Garcia Zanati, Sassaki, Ligia Yukie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237008/
https://www.ncbi.nlm.nih.gov/pubmed/37274378
http://dx.doi.org/10.4330/wjc.v15.i5.217
_version_ 1785053068089360384
author Grillo, Thais Gagno
Silveira, Caroline Ferreira da Silva Mazeto Pupo
Quaglio, Ana Elisa Valencise
Dutra, Renata de Medeiros
Baima, Julio Pinheiro
Bazan, Silmeia Garcia Zanati
Sassaki, Ligia Yukie
author_facet Grillo, Thais Gagno
Silveira, Caroline Ferreira da Silva Mazeto Pupo
Quaglio, Ana Elisa Valencise
Dutra, Renata de Medeiros
Baima, Julio Pinheiro
Bazan, Silmeia Garcia Zanati
Sassaki, Ligia Yukie
author_sort Grillo, Thais Gagno
collection PubMed
description Tumor necrosis factor inhibitors (anti-TNFs) are widely used therapies for the treatment of inflammatory bowel diseases (IBD); however, their administration is not risk-free. Heart failure (HF), although rare, is a potential adverse event related to administration of these medications. However, the exact mechanism of development of HF remains obscure. TNFα is found in both healthy and damaged hearts. Its effects are concentration- and receptor-dependent, promoting either cardio-protection or cardiomyocyte apoptosis. Experimental rat models with TNFα receptor knockout showed increased survival rates, less reactive oxygen species formation, and improved diastolic left ventricle pressure. However, clinical trials employing anti-TNF therapy to treat HF had disappointing results, suggesting abolishment of the cardioprotective properties of TNFα, making cardiomyocytes susceptible to apoptosis and oxidation. Thus, patients with IBD who have risk factors should be screened for HF before initiating anti-TNF therapy. This review aims to discuss adverse events associated with the administration of anti-TNF therapy, with a focus on HF, and propose some approaches to avoid cardiac adverse events in patients with IBD.
format Online
Article
Text
id pubmed-10237008
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-102370082023-06-03 Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature Grillo, Thais Gagno Silveira, Caroline Ferreira da Silva Mazeto Pupo Quaglio, Ana Elisa Valencise Dutra, Renata de Medeiros Baima, Julio Pinheiro Bazan, Silmeia Garcia Zanati Sassaki, Ligia Yukie World J Cardiol Minireviews Tumor necrosis factor inhibitors (anti-TNFs) are widely used therapies for the treatment of inflammatory bowel diseases (IBD); however, their administration is not risk-free. Heart failure (HF), although rare, is a potential adverse event related to administration of these medications. However, the exact mechanism of development of HF remains obscure. TNFα is found in both healthy and damaged hearts. Its effects are concentration- and receptor-dependent, promoting either cardio-protection or cardiomyocyte apoptosis. Experimental rat models with TNFα receptor knockout showed increased survival rates, less reactive oxygen species formation, and improved diastolic left ventricle pressure. However, clinical trials employing anti-TNF therapy to treat HF had disappointing results, suggesting abolishment of the cardioprotective properties of TNFα, making cardiomyocytes susceptible to apoptosis and oxidation. Thus, patients with IBD who have risk factors should be screened for HF before initiating anti-TNF therapy. This review aims to discuss adverse events associated with the administration of anti-TNF therapy, with a focus on HF, and propose some approaches to avoid cardiac adverse events in patients with IBD. Baishideng Publishing Group Inc 2023-05-26 2023-05-26 /pmc/articles/PMC10237008/ /pubmed/37274378 http://dx.doi.org/10.4330/wjc.v15.i5.217 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Grillo, Thais Gagno
Silveira, Caroline Ferreira da Silva Mazeto Pupo
Quaglio, Ana Elisa Valencise
Dutra, Renata de Medeiros
Baima, Julio Pinheiro
Bazan, Silmeia Garcia Zanati
Sassaki, Ligia Yukie
Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature
title Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature
title_full Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature
title_fullStr Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature
title_full_unstemmed Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature
title_short Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature
title_sort acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: a review of the literature
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237008/
https://www.ncbi.nlm.nih.gov/pubmed/37274378
http://dx.doi.org/10.4330/wjc.v15.i5.217
work_keys_str_mv AT grillothaisgagno acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature
AT silveiracarolineferreiradasilvamazetopupo acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature
AT quaglioanaelisavalencise acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature
AT dutrarenatademedeiros acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature
AT baimajuliopinheiro acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature
AT bazansilmeiagarciazanati acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature
AT sassakiligiayukie acuteheartfailureasanadverseeventoftumornecrosisfactorinhibitortherapyininflammatoryboweldiseaseareviewoftheliterature